Specifically, we assessed (1) the feasibility of an orthotopic replacement of the endogenous TCR with a TCR containing a CHM1 targeting sequence, (2) TCR expression, as well as tumor recognition and cytotoxicity function of CRISPR/Cas9-engineered T cells, (3) comparative prevention of endogenous TCR expression in CRISPR/Cas9 vs. retrovirally engineered T cells, and finally (4) characterization of CHM1 as a unique target. Here, CNMD is linked to neoplasm.